Pilling

Co-Author of the Karolinska 1000 Consecutive MANTA® Vascular Closure Device Study to Present Learnings at the Transcatheter Cardiovascular Therapeutics (TCT) 2022 Conference

Retrieved on: 
Thursday, September 15, 2022
Weck, Health, MANTA, Karolinska Institute, NYSE, Canadian International Council, SAFE, Anesthesia, VCDS, CRF, Percutaneous, Device, LMA, Interventional cardiology, TAVI, U.S. Securities and Exchange Commission, Patient, Emergency medicine, Karolinska University Hospital, Solution, Annual report, Clinical trial, Teleflex, VCD, International Journal of Cardiology, Security (finance), 1048, Observational study, GLOBE, Prostatic urethral lift, Urology, Catheter, Veni, vidi, vici, TFX, TCT, Radiology, MARVEL, Medical device, Medical imaging, Cardiology, Pilling, QuikClot

TCT is the Cardiovascular Research Foundation's (CRF) annual scientific symposium and the world's foremost educational forum specializing in interventional cardiovascular medicine.

Key Points: 
  • TCT is the Cardiovascular Research Foundation's (CRF) annual scientific symposium and the world's foremost educational forum specializing in interventional cardiovascular medicine.
  • The findings of our study indicate that the MANTA Device is easy to learn and has a short learning curve, which is in line with our user experience.
  • The MANTA Device is the first commercially available biomechanical vascular closure device designed specifically for large bore femoral arterial access site closure.
  • Percutaneous plug-based vascular closure device in 1000 consecutive transfemoral transcatheter aortic valve implantations.

Teleflex Announces First Patient Enrollment in MANTA Ultra Study

Retrieved on: 
Wednesday, June 22, 2022
Cardiology, Security (finance), Length of stay, Franzone, Frequency, Consultant, University, Health, LMA, Associate, GLOBE, Solution, Annual report, Disease, Radiology, Surgeon, Weck, Hemostasis, Haynes, TAVR, Head, University at Buffalo Law School, Meta-analysis, Systematic review, Vascular closure device, Patient, MANTA, BMC, U.S. Securities and Exchange Commission, NYSE, Risk, TAVI, Trial of the century, Mortality, Teleflex, Safety, TFX, Urology, Prostatic urethral lift, U/S, Aortic valve, Anesthesia, Emergency medicine, Medical imaging, MD, QuikClot, Medicine, Pilling

The study will enroll patients undergoing elective TAVR procedures with planned percutaneous femoral arterial access.

Key Points: 
  • The study will enroll patients undergoing elective TAVR procedures with planned percutaneous femoral arterial access.
  • The resourcing of the MANTA Ultra Study by Teleflex reflects our commitment to providing interventional cardiologists and surgeons with category-defining tools that enable difficult procedures and minimize complications in this case, the complications attributable to large bore access that are inherent to TAVI procedures, said Teleflex Medical Director, Chris Buller, MD.
  • Were excited to embark on the Teleflex MANTA Ultra study, said Dr. Wood.
  • With visualization of the access site during MANTA Device deployment, the study intends to demonstrate that ultrasound allows for precise deployment and positive positioning of the MANTA Device anchor within the vessel.

Teleflex Announces Health Canada Approval of MANTA® Vascular Closure Device

Retrieved on: 
Wednesday, May 18, 2022
Hemostasis, Population, General manager, U.S. Securities and Exchange Commission, Percutaneous, LMA, MD, MANTA, SAFE, Weck, Patient, TFX, Solution, Health, Emergency medicine, Â, Anesthesia, TEVAR, Clinical trial, Urology, Prostatic urethral lift, IDE, Hospital, Vascular closure device, TAVR, Health Canada, Security (finance), Device, Radiology, NYSE, Annual report, GLOBE, Medical device, Medical imaging, Teleflex, Pilling, QuikClot

WAYNE, Pa., May 18, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today has announced that it received Health Canada approval for the MANTA Vascular Closure Device the first commercially available biomechanical vascular closure device designed specifically for large bore femoral arterial access site closure.1 This approval marks an important milestone in the regulatory plan to expand the availability of the MANTA Device globally and provides access to another uniquely designed device from Teleflex to Canadian clinicians.

Key Points: 
  • WAYNE, Pa., May 18, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today has announced that it received Health Canada approval for the MANTA Vascular Closure Device the first commercially available biomechanical vascular closure device designed specifically for large bore femoral arterial access site closure.1 This approval marks an important milestone in the regulatory plan to expand the availability of the MANTA Device globally and provides access to another uniquely designed device from Teleflex to Canadian clinicians.
  • Our team has been working diligently to obtain this approval and were confident that Health Canada would recognize the benefits of the MANTA Device, said Scott Holstine, President and General Manager of the Teleflex Interventional Business Unit.
  • Percutaneous vascular closure obtained with the MANTA Device without the use of unplanned endovascular or surgical intervention.
  • A single MANTA Vascular Closure Device was deployed in 99.6% of subjects in IDE trial.